Insider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 20,000 Shares of Stock

Key Points

• Reprogrammed Interchange LLC, the major shareholder of Vor Biopharma, recently sold a total of 400,000 shares for $656,000, bringing their ownership down to approximately 33.2 million shares.
• Vor Biopharma's stock price saw a decline, trading down 8.0% to $1.60, with a year-long trading range between a low of $0.13 and a high of $3.29.
• Analysts maintain a generally positive outlook, with five analysts rating the stock as a Buy and a consensus target price of $6.07.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $32.80, for a total value of $656,000.00. Following the transaction, the insider owned 1,661,424 shares of the company's stock, valued at $54,494,707.20. The trade was a 1.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The shares were sold at an average price of $1.54, for a total value of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.80, for a total value of $688,780.40.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The shares were sold at an average price of $35.00, for a total value of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The shares were sold at an average price of $36.60, for a total value of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The shares were sold at an average price of $39.80, for a total value of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The shares were sold at an average price of $36.40, for a total value of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total value of $898,440.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $39.40, for a total value of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 22,650 shares of Vor Biopharma stock. The stock was sold at an average price of $38.60, for a total value of $874,290.00.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 27,730 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total value of $1,109,200.00.

Vor Biopharma Stock Performance

Shares of VOR stock traded down $3.16 during trading hours on Friday, reaching $27.24. The company had a trading volume of 654,392 shares, compared to its average volume of 380,475. The stock has a fifty day moving average of $40.37 and a 200-day moving average of $22.88. The company has a market capitalization of $3.45 billion, a price-to-earnings ratio of -16.51 and a beta of 2.05. Vor Biopharma Inc. has a 12-month low of $2.62 and a 12-month high of $65.80.

Hedge Funds Weigh In On Vor Biopharma

Large investors have recently bought and sold shares of the business. Money Concepts Capital Corp increased its holdings in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new position in Vor Biopharma in the second quarter valued at $66,000. OMERS ADMINISTRATION Corp acquired a new position in Vor Biopharma in the first quarter valued at $100,000. Finally, Trustees of Columbia University in the City of New York acquired a new position in Vor Biopharma in the fourth quarter valued at $102,000. Hedge funds and other institutional investors own 97.29% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on VOR. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. HC Wainwright restated a "buy" rating and set a $60.00 price target on shares of Vor Biopharma in a research note on Thursday, August 14th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $121.33.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.